MannKind Secures Up to $500 Million in Strategic Financing from Blackstone
Deal News | Aug 06, 2025 | Blackstone
MannKind Corporation, a firm specializing in inhaled therapeutics, has announced a strategic financing agreement with Blackstone, valued at up to $500 million. This non-dilutive financing package is poised to enhance MannKind's capital flexibility, invigorate its growth aspirations, and support potential expansions, notably the preparation for a potential pediatric launch of its leading product, Afrezza. The package includes a $75 million term loan immediately available, followed by a potential $125 million and an uncommitted $300 million, contingent on meeting customary conditions. The capital injection is seen as fostering MannKind's ongoing developments within the endocrine and orphan lung diseases sects, enabling expanded commercial functions and progressing its innovation pipeline. Blackstone's engagement positions them as a critical strategic partner, promising access to their expansive life sciences expertise which can prop MannKind's expansion and commercialization goals.
Sectors
- Biotechnology
- Private Equity
- Life Sciences
Geography
- United States – Both MannKind and Blackstone operate primarily in the United States, with activities mentioned in geographical terms around Danbury, Connecticut, Westlake Village, California, and New York.
Industry
- Biotechnology – Relevant as MannKind focuses on inhaled therapeutic products and drug delivery technologies.
- Private Equity – Blackstone is engaged as a private equity partner providing strategic funding to MannKind.
- Life Sciences – The collaboration highlights Blackstone's interest in supporting life sciences initiatives, given MannKind's focus on life-impacting therapies.
Financials
- $500 million – Total value of the strategic financing agreement between MannKind and Blackstone.
- $75 million – Initial term loan amount provided at the closing of the deal.
- $125 million – Delayed draw term loan available over the next 24 months, subject to conditions.
- $300 million – Additional uncommitted delayed draw term loan available at the mutual consent of MannKind and Blackstone.
- SOFR + 4.75% – Interest rate for the senior secured credit facility, adjustable under certain leverage conditions.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| MannKind Corporation | Target | Company | A biotechnology company focused on inhaled therapeutic products, especially for endocrine and orphan lung diseases. |
| Blackstone | Bidding Company | PE Firm | The largest alternative asset manager providing up to $500 million financing to MannKind. |